The first patient dosed in Australia with INNOGEN-B(02591) in a Phase II clinical trial for the treatment of obesity and overweight with exenatide alpha was completed.
Silver Noble Pharmaceuticals-B (02591) announces that on August 25, 2025, the company has completed the acquisition in Australia...
INNOGEN-B (02591) announces that on August 25, 2025, the company has dosed the first patient in Australia with IISupageglutide-alpha for the treatment of obesity and overweight in a phase II clinical trial. The company anticipates that approximately 200 participants will be enrolled in this clinical trial.
Related Articles
US Stock Market Move | Ethereum concept stocks rose sharply, with SharpLink Gaming (SBET.US) rising more than 3.4%.
US Stock Market Move | Q2 net sales hit a record high, Semtech Corporation (SMTC.US) surged more than 16%
Macau L.J. (01680) issues profit warning, expecting a decrease of approximately 12% in the total reported earnings for the mid-term compared to the same period last year.
US Stock Market Move | Ethereum concept stocks rose sharply, with SharpLink Gaming (SBET.US) rising more than 3.4%.
US Stock Market Move | Q2 net sales hit a record high, Semtech Corporation (SMTC.US) surged more than 16%
Macau L.J. (01680) issues profit warning, expecting a decrease of approximately 12% in the total reported earnings for the mid-term compared to the same period last year.
RECOMMEND
Analysts Respond to Trump’s Dismissal of Fed Governor Cook as a Further Assault on Central Bank Independence
26/08/2025
U.S. Proposes Including Copper, Silicon, Silver on 2025 Critical Minerals List Amid Supply Chain Concerns
26/08/2025
Trump Vows to Slash U.S. Drug Prices by Up to 1500%, Triggering Sell-Off in Pharma Stocks
26/08/2025
